Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Vanguard Information Technology Index Fund ETF (VGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Vanguard Information Technology Index Fund ETF — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Vanguard Information Technology Index Fund ETF trades at $121.5 (market cap $170.20B). The key difference: Vanguard Information Technology Index Fund ETF is far larger — about 22.6× Spyre Therapeutics Inc. Common Stock's market cap, and Vanguard Information Technology Index Fund ETF is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Vanguard Information Technology Index Fund ETF for 130 Days on average.
| SYRE | VGT | |
|---|---|---|
Market Cap | $7.52B | $170.20B |
Volume | 1,441,031 | 2,835,027 |
Sector | Health | — |
52-Week High | $108.92 | $129.79 |
52-Week Low | $22.18 | $83.59 |
Typical Hold Time | 0 Days | 130 Days |
Enterprise Value | $6.52B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Vanguard Information Technology ETF (VGT) trades at $126.48, down 0.02% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF, focused on U.S. technology stocks, lacks key valuation ratios in the provided data but has demonstrated strong historical performance, with news highlighting past annualized returns exceeding 17% over two decades. Recent articles emphasize its low expense ratio and concentration in top tech holdings like Nvidia, Apple, and Microsoft.
The outlook for VGT remains positive given technology sector growth and AI-driven momentum, but risks include high concentration in a few stocks and sensitivity to tech sector volatility. Long-term investors may benefit from its historical outperformance, though diversification and expense ratios compared to peers like IYW or QQQ warrant consideration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Vanguard Information Technology Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →
